

Hydroxyurea appears beneficial in patients with beta-thalassaemia major and intermedia

S Fadilah S Abdul Wahid^{1,2}, Rozilaila Rahmat¹, Shamsul Azhar³, Noor Hamidah Hussin⁴, Cheong Soon Keng⁵

Abstrak

Pasien dengan kelainan bawaan pada rantai β -globin mungkin mengalami gejala penyakit yang lebih ringan jika mereka menghasilkan hemoglobin fetal (HbF) dengan kadar yang tinggi. Penggunaan hydroxyurea (HU) telah memperlihatkan peningkatan kadar HbF pada pasien penyakit 'sickle cell', dan mungkin berguna pada β -thalassemia. Kami memberi terapi HU kepada 13 pasien β -thalassemia intermedia atau mayor, termasuk 6 pasien splenektomi. Pasien-pasien diberi dosis eskalasi (10 sampai 25 mg/kg/h) HU selama sekitar 2 tahun (median: 21 bulan, 'range': 8 – 55 bulan). Sebelas pasien menunjukkan respons kenaikan HbF pada pra-transfusi, masing-masing dari median awal 8,0% (2,5 - 61,3%) menjadi 28,0% (6,6 - 49,2%) dan 40,7% (4,8 - 72,3%) pada 3 bulan dan 18 bulan pasca terapi HU. Kenaikan yang sama pada nilai median Hb terlihat pada 1, 3 dan 18 bulan terapi HU. Enam dari 7 pasien yang tergantung transfusi yang menunjukkan kenaikan HbF (seorang dengan β -thalassemia mayor), juga memperlihatkan penurunan kebutuhan transfusi setelah dua tahun terapi HU. Respons terhadap HU juga terlihat dengan adanya pengecilan limpa. Selain ulkus di mulut yang menghilang dengan penurunan dosis HU, tidak terlihat toksisitas lain yang bermakna. Dapat disimpulkan bahwa pemberian HU pada pasien β -thalassemia menyebabkan peningkatan produksi HbF disertai perbaikan pada eritropoiesis, tanpa toksisitas yang bermakna. (*Med J Indones* 2007; **16**:78-83)

Abstract

*Patients with severe inherited β -globin chain disorders may have milder illness if they produce high levels of fetal hemoglobin (HbF). Hydroxyurea (HU) has been shown to enhance HbF levels in patients with sickle cell disease and may be useful in β -thalassemias. We administered HU to 13 patients with β -thalassemia intermedia or major, including 6 splenectomized patients. The patients received escalating doses (10 to 25 mg/kg/d) of HU for around 2 years (median: 21 months, range: 8 - 55 months). Eleven patients responded with an increase in the pre-transfusion HbF levels, from a base line median of 8.0% (2.5 - 61.3%) to 28.0% (6.6 - 49.2%) and 40.7% (4.8 - 72.3%) at 3 months and 18 months post-HU, respectively. A concomitant increment in median hemoglobin levels was noted at 1, 3 and 18 months of HU therapy. Six of 7 transfusion-dependent patients who had an increment of HbF (one with β -thalassemia major) also had reduced transfusion requirement over the 2-year period of HU therapy. Response to HU was also shown by a reduction in spleen size. Apart from oral ulcers that resolved upon dose reduction of HU, no significant toxicity was noted. We conclude that increased HbF production in β -thalassemia patients, with an improvement in erythropoiesis, can be achieved using HU with minimal toxicity. (*Med J Indones* 2007; **16**:78-83)*

Keywords: fetal hemoglobin (HbF), erythropoiesis, toxicity

β -thalassemia is the most common inherited blood disorders in South Asia that results from a number of genetic

defects in β -globin gene expression.¹ Deficient synthesis of β -chain leads to imbalance globin chain synthesis with an excess of α -globin, which precipitates, causing ineffective erythropoiesis and shortened survival of red cells. Patients with severe β -thalassemia require regular red cell transfusion to sustain their lives.² However, most individuals so affected usually die before the age of 25 as a direct result of cardiac iron deposition unless treated concomitantly with chelation therapy.³ Thus, an important caveat in the management of β -thalassemia is to find an alternative approach to red cell transfusion.

¹ Clinical Hematology and Stem Cell Transplantation Services, Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

² Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

³ Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

⁴ Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

⁵ Department of Medicine, International Medical University, Seremban, Malaysia

Hydroxyurea (HU) is one of several agents capable of activating the γ -globin gene associated with an improvement in α :non- α globin ratios, thereby leading to an increase in the effectiveness of erythropoiesis after several months of therapy.^{2,4} Because it has the lowest toxicity profile² among the chemotherapeutic agents thus far employed, HU has been widely used for this purpose. Numerous studies have demonstrated that HU therapy can enhance HbF production and ameliorate the clinical course of sickle cell disease (SCD) with three or more painful crises per year with only mild myelotoxicity.⁵ However, there has been limited and mainly negative information on the effect of HU in thalassemia.⁶ Therefore, we undertake this study to gain a better understanding on the effects and safety of HU in β -thalassemia patients.

METHODS

Upon obtaining approval from institutional review board and ethics committee at the Faculty of Medicine, Universiti Kebangsaan Malaysia and informed consent,⁷ HU was administered according to the NIH protocol¹ to consecutive patients with β -thalassemia. All of them were treated at the outpatient Hematology clinic of Hospital Universiti Kebangsaan Malaysia (Kuala Lumpur, Malaysia) with regular follow-up every 2 to 4 weeks.

The patients were initially treated with a dose of HU of approximately 10 mg/kg/day (rounded up to the next 500 mg) in one dose orally over 4 consecutive days/week, and in the absence of hematologic toxicity the dose was increased by 5 mg/kg/day every 4 weeks to a maximal total dose of 25 mg/kg (rounded up to 1 to 1.5 g) daily and continued for around 2 years. Evidence of hematologic toxicity was defined as a white blood cell count (WBC) of less than $4 \times 10^9/L$ (or neutrophil count of less than $1 \times 10^9/L$) or platelet count (PC) of less than $80 \times 10^9/L$. The levels of pre-transfusion Hb and HbF, full blood count, serum LDH levels, serum bilirubin and spleen size were evaluated before and every 2 to 4 weeks during treatment and the study was conducted from 2001 to 2005. HbF quantitation was performed using the high-performance liquid chromatography.

Data collected were analyzed using SPSS-PC (version 13.0) for windows. Statistical analysis to determine differences between the data sets depended on the type of distribution and variance. When the distributions were

normal and the variances were homogenous, time series analysis of variance (ANOVA) would be used to determine the differences between the data sets. However, when the distributions were not normal or the variances not homogenous, statistical method used to determine the significance of the differences between the data sets and the baseline data was the Wilcoxon Signed Rank Test and *P* values of < 0.05 were considered significant.

RESULTS

We got 13 patients with β -thalassemia (5 patients with β -thalassemia major and 8 with β -thalassemia intermedia), including 6 patients who had prior splenectomy. There were 8 males and 5 females, aged between 15 to 52 years (mean \pm SD = 28.4 ± 13.6).

We treated the 13 patients with escalating doses of HU for a median of 21 (range: 8 - 55) months. Ten of thirteen patients responded with a mean increase of 56% in pre-transfusion HbF levels, from a baseline median (range) of 8.0% (2.5 - 61.3%) to 20.1% (3.0 - 80.3%) after 6 months of treatment and 33.9% (2.6 - 81.5%) at 12 months post-HU, respectively (Figure 1). The median (range) of HbF level started to increase as early as 3 months post-HU to 28.0% (6.6 - 49.2%) with the highest level noted at 18 months post-HU that was 40.7% (4.8 - 72.3%) and remained elevated at 2 years of HU therapy that was 39.9% (39.4 - 51.5%). Three patients with β -thalassemia intermedia did not show a consistent pattern of increment and were labeled as non-responders to HU therapy.

Apart from the age, the data analysed in this study did not follow a normal distribution. Therefore statistical method used to determine the significance of the differences in the paired sets of data (between baseline data and data after therapy) was the Wilcoxon Signed Rank Test and *P* values of < 0.05 were considered significant.

Increment in median HbF levels was observed at 3 months of HU therapy in patients with prior splenectomy and at 12 months of HU in patients with β -thalassemia intermedia and patients who had undergone splenectomy (*P* < 0.05, Table 1, 2). Six of 7 transfusion-dependent patients who experienced an increment of HbF also had reduced red cell transfusion requirement after HU therapy. Over a 2-year period of HU therapy, all 5 β -thalassemia intermedia patients who were transfusion-dependent had a median reduction of 350 mls of a 2 monthly red-cell

transfusion while one β -thalassemia major patient had a median reduction of 500 mls of a 2 monthly red-cell transfusion. The increment in the median [range] of pre-transfusion hemoglobin (Hb) level began at one-month post-HU (8.4 g/dL [6.8 - 11.5 g/dL]) and peaked at 3 months (8.7 g/dL [6.0 - 11.4]); compared to the median [range] of baseline level of below 7 g/dL (6.7 g/dL [5.7 - 10.8]), there were significant differences ($P < 0.05$). The median [range] of Hb level continued to increase at 12 months, then declined at 18 months of HU therapy to 7.3 g/dL [5.0 - 10.0 g/dL] and in one patient with β -thalassemia intermedia the Hb levels dropped to below the baseline levels at 24 months post-HU (Figure 2).

Increment in median Hb levels was observed in patients with β -thalassemia intermedia and β -thalassemia major at 3 months of HU therapy and in patients with prior splenectomy at 3 and 12 months of HU therapy ($P < 0.05$, Table 1, 2). The MCV and MCH started to increase in the first month after HU commencement with a maximum increase at 3 to 6 months of HU therapy ($P < 0.05$) and MCV remained increased at 24 months of therapy and the increment was more prominent in patients with β -thalassemia intermedia and patients without prior splenectomy. Although not statistically significant, we observed a downward trend in the serum LDH and unconjugated bilirubin levels.




Figure 1. Changes in the level of pre-transfusion HbF in patients with β -thalassemia treated with HU




Figure 2. Changes in the level of pre-transfusion Hb in patients with β -thalassemia treated with HU

The reduction in the spleen size was noted after 6 months of HU and was most prominent at 12 months of HU therapy. Most patients also reported an improvement in well being and effort tolerance. There was no significant

decline in the WBC and PC in all 4 groups of patients (Table 1, 2). Other adverse effects reported included skin hyper pigmentation in a patient and oral ulcers in 2 patients that resolved upon dose reduction of HU.

Table 1. Pre-transfusion data in patients with β -thalassemia intermedia and major treated with HU

Parameters	Baseline (median, range)	3 months on HU (median, range)	P value	12 months on HU (median, range)	P value	18 months on HU (median, range)	P value
<i>β-thalassemia intermedia (8 patients)</i>							
HbF (%)	19.5, 2.5-61.3	31.0, 10.0-49.2	0.285	37.8, 3.4-80.3	0.043*	40.7, 34.2-72.3	0.109
Hb (g/dL)	7.4, 5.4-10.0	8.8, 6.6-11.0	0.043*	8.1, 7.1-10.5	0.175	7.9, 6.9-11.2	0.345
MCV (fl)	80.6, 61.7-84.4	87.3, 70.0-96.2	0.017*	82.4, 66.8-88.7	0.043*	82.5, 66.8-88.7	0.028*
MCH (pg)	26.9, 18.7-30.5	28.9, 21.9-34.6	0.025*	26.0, 21.0-29.3	0.672	24.6, 18.7-30.4	0.138
WBC ($\times 10^9/L$)	12.9, 4.1-38.3	7.6, 4.0-20.7	0.161	8.2, 4.1-67.5	0.686	7.3, 4.4-58.0	0.686
Platelet ($\times 10^9/L$)	294.5, 34.0-644.0	316.5, 60.0-614.0	0.779	417.0, 109.0-732.0	0.866	256.0, 69.0-611.0	0.686
Se.LDH (μ L)	952.5, 378.0-1804.0	648.5, 364.0-1517.0	0.345	483.0, 366.0-600.0	0.180	-	-
Unconjugated bilirubin (μ mol/L)	53.0, 40.0-79.0	60.5, 43.0-85.0	1.000	45.0, 32.0-73.0	0.271	45.0, 32.0-73.0	0.655
Spleen size (cm)	10.5, 5.0-15.0	12.0, 4.0-12.0	0.180	10.0, 2.0-14.5	0.109	6.0, 4.0-16.0	0.285
<i>β-thalassemia major (5 patients)</i>							
HbF (%)	8.0, 3.5-35.0	24.9, 6.6-39.0	0.109	21.6, 3.8-54.1	0.068	24.5, 4.8-44.2	0.180
Hb (g/dL)	7.3, 5.0-8.9	8.7, 6.0-11.4	0.043*	9.5, 7.6-12.7	0.109	7.9, 5.5-9.5	0.109
MCV (fl)	78.5, 58.6-86.8	81.3, 71.4-84.1	0.225	79.0, 69.3-87.3	0.109	77.4, 72.7-87.4	0.285
MCH (pg)	26.2, 17.1-29.9	26.2, 22.5-28.6	0.273	27.7, 23.4-28.9	0.285	28.2, 23.6-30.2	0.109
WBC ($\times 10^9/L$)	12.8, 4.3-38.7	7.1, 4.5-14.0	0.138	6.8, 6.5-21.9	1.000	4.9, 4.5-11.7	0.593
Platelet ($\times 10^9/L$)	233.0, 64.0-484.0	190.0, 50.0-295.0	0.080	149.0, 10.7-430.0	1.000	126.0, 50.0-268.0	0.593
Se.LDH (μ L)	866.0, 556.0-1068.0	468.0, 431.0-922.0	0.109	736.0, 315.0-748.0	0.068	-	-
Unconjugated bilirubin (μ mol/L)	56.0, 16.0-89.0	64.0, 31.0-85.0	1.000	63.0, 12.0-81.0	0.144	74.0, 12.0-76.0	1.000
Spleen size (cm)	11.0, 9.0-13.0	10.0, 9.5-11.0	0.285	10.5, 10.0-11.0	0.180	-	-

* P < 0.05

Table 2. Pre-transfusion data in patients with β -thalassemias with or without splenectomy treated with HU

Parameters	Baseline (median, range)	3 months on HU (median, range)	P value	12 months on HU (median, range)	P value	18 months on HU (median, range)	P value
<i>Splenectomized (6 patients)</i>							
HbF (%)	7.5, 2.5-61.3	15.8, 3.4-80.3	0.043*	13.3, 2.6-1.5	0.068	-	-
Hb (g/dL)	8.1, 6.5-10.0	9.2, 7.6-11.4	0.056	8.2, 7.4-12.7	0.345	8.2, 6.9-9.5	0.715
MCV (fl)	83.4, 79.5-86.8	85.0, 78.6-94.2	0.345	87.3, 77.6-89.5	0.138	87.6, 81.8-88.7	0.066
MCH (pg)	29.3, 27.2-30.5	28.9, 25.9-34.6	0.600	27.7, 25.7-29.3	0.043*	29.3, 26.2-30.4	0.465
WBC ($\times 10^9/L$)	32.3, 15.4-38.7	13.0, 7.1-20.7	0.046*	24.4, 7.5-67.5	0.715	17.6, 11.7-58.0	0.593
Platelet ($\times 10^9/L$)	459.0, 377.0-644.0	424.0, 190.0-614.0	0.116	484.0, 417.0-732.0	0.686	483.0, 268.0-611.0	0.590
Se.LDH (μ L)	1124.5, 392.0-1804.0	780.0, 431.0-1517.0	0.893	-	-	-	-
Unconjugated bilirubin (μ mol/L)	43.0, 16.0-79.0	51.0, 31.0-63.0	0.715	59.0, 12.0-73.0	0.345	-	-
<i>Non-Splenectomized (7 patients)</i>							
HbF (%)	26.2, 3.5-35.0	31.0, 10.0-49.2	0.080	37.8, 3.8-54.3	0.043*	37.5, 4.8-44.2	0.068
Hb (g/dL)	7.0, 5.0-10.0	7.9, 6.6-11.0	0.027*	7.8, 7.1-10.5	0.043*	7.8, 5.5-11.2	0.043*
MCV (fl)	71.4, 58.6-84.2	84.1, 70.0-96.2	0.018*	75.2, 67.2-98.1	0.043*	73.6, 66.8-83.1	0.080
MCH (pg)	21.7, 17.1-26.6	26.2, 21.9-29.6	0.028*	25.6, 21.0-28.9	0.043*	23.0, 18.7-28.2	0.273
WBC ($\times 10^9/L$)	4.9, 4.1-12.8	5.6, 4.0-9.8	0.398	6.5, 4.1-8.8	0.715	4.5, 4.4-7.3	0.345
Platelet ($\times 10^9/L$)	146.0, 34.0-233.0	110.0, 50.0-247.0	0.750	136.0, 107.0-188.0	0.686	126.0, 50.0-256.0	0.686
Se.LDH (μ L)	761.0, 378.0-1144.0	511.0, 364.0-922.0	0.500	668.0, 366.0-748.0	0.144	545.0, 472.0-618.0	0.144
Unconjugated bilirubin (μ mol/L)	56.0, 42.0-89.0	66.5, 43.0-85.0	0.917	54.0, 41.0-81.0	0.116	64.0, 40.0-76.0	0.715
Spleen size (cm)	11.0, 5.0-15.0	10.5, 4.0-12.0	0.080	10.0, 2.0-14.5	0.042*	10.0, 4.0-16.0	0.104

* P < 0.05

DISCUSSION

Pharmacological stimulation of HbF production is of considerable interest as an alternative approach to the therapy of severe thalassemia. Hydroxyurea therapy could increase the HbF production in β -thalassemia patients due to an improvement in the α :non- α globin ratio.^{2,4} Hydroxyurea has been shown to increase total Hb and HbF levels and reduce the need for blood transfusion in a patient with transfusion-dependent β -thalassemia.⁸ In contrast, Loukopoulos *et al*⁹ showed that HU therapy resulted in a significant increase in HbF with no change in total Hb levels in patients with β -thalassemia intermedia. Thus, the effectiveness of HU in the thalassemia syndromes is still controversial.

Our results demonstrated that HU therapy was associated with an improvement in the ineffective erythropoiesis as reflected by an increase in the Hb level, a reduction in red cell transfusion requirement and a decreasing trend in the serum LDH and serum unconjugated bilirubin levels. This favorable effect of HU was observed as early as 1 to 3 months of HU treatment. In contrast, a significant decrease in spleen size reflecting a reduction in extramedullary erythropoiesis appeared to take place much later, after 6 months of HU therapy with a maximal benefit observed at 12 months of HU therapy. These favorable effects of HU appeared to be associated with an increase in the γ -globin biosynthesis, because the percentage of HbF increased as well as the total Hb. This observation is in agreement with a short-term study that showed a good correlation of Hb levels with the amount of HbF production in patients with β^0 -thalassemia/HbE treated with HU for 5 months.⁴ However, we showed that the increment in total Hb became less remarkable after 18 months of HU therapy despite being on a stable dose of HU. Interestingly, while there was a decline in the total Hb, the HbF level remained elevated. This intriguing observation suggest that increasing HbF further may not necessarily resulted in a concomitant increase in total Hb in particular after one year of therapy, and HbF increment *per se* is not adequate for maintaining optimum Hb level in patients with β -thalassemia. Indeed, the decrement in Hb level was less likely due to myelotoxicity as there was no concomitant reduction in the leukocyte and platelet counts.

In addition to the modest increase in the Hb, most patients reported an increase in exercise tolerance and sense of well being in comparison with their symptoms before therapy. This feeling may reflect the significant decrease in ineffective erythropoiesis resulting in the

replacement of the poorly hemoglobinised, prematurely dying erythroid progenitor and red cell population by another population of cells with higher Hb content and longer survival, the regeneration of which requires less energy and consumption.⁹ In patients who exhibit a β -thalassemia intermedia phenotype, even a modest increase in red cell production with coincident reduction in ineffective erythropoiesis might be highly beneficial as the need of red cell transfusion might be delayed or eliminated. We showed that 6 of 7 transfusion-dependent patients (5 β -thalassemia intermedia and one β -thalassemia major) who experienced an increment of HbF also had reduced red cell transfusion requirement after HU therapy.

The cutaneous side-effects of HU, which were the commonest side-effects, were seen in only 3 patients, and these resolved by dose modification. The development of adverse cutaneous reactions due to HU appeared to depend on the underlying demographic and medical features of patients. In general, these reactions are more likely to develop in patients with SCD than in thalassemia as patients with SCD have darker baseline pigmentation as well as chronic microangiopathy, putting them at risk for both pigmentary and ulcerative complications.¹⁰ The maximal tolerated dose of HU of 25 mg/kg/day was achieved by 6 months of HU therapy and importantly, it was not associated with significant myelotoxicity in the majority of patients.

Overall, the outcome of this study on the effects of HU in a cohort of β -thalassemia patients has been encouraging. However, 3 patients with β -thalassemia intermedia did not show a consistent increment in HbF level. These non-responders might be due to poor compliance or they harbored genetic defects that were different from the responders. It is now very important to determine whether these unusual responses reflect the action of the particular underlying thalassemia mutations¹¹ or whether other mechanisms are involved. Another problem, which requires further exploration, is whether a combination of agents that can increase HbF may be more effective than single agent (examples, erythropoietin and azacytidine), and, if so, the precise regimen of administration of these agents needs to be addressed. Thirdly, it will be interesting to see whether induction of HbF synthesis in patients with severe β -thalassemia can eliminate their long-term transfusion requirement.

We conclude that a significant increase in HbF production in β -thalassemia patients associated with

an improvement in erythropoiesis, can be achieved using HU with minimal toxicity. This beneficial effect and safety profile of HU in this population would need to be confirmed in a further study with a larger number of patients.

Acknowledgements

We are grateful to Ms. Rozie Hanisa Musa from the National Blood Center, Kuala Lumpur, Malaysia for her excellent technical assistance and Dr. Leong Chooi Fun for his assistance in patient recruitment. This work was supported by grants from the Intensification of Research in Priority Areas (IRPA-06–02–02–091) and Hospital Universiti Kebangsaan Malaysia (HUKM F1-99), Kuala Lumpur, Malaysia.

REFERENCES

1. Kazazian HH, Boehm CD. Molecular basis and prenatal diagnosis of beta-thalassemia. *Blood*. 1988; 72: 1107–16.
2. Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Schechter AN, et al. Hydroxyurea therapy in beta-thalassemia intermedia: improvement in hematological parameters due to enhanced beta-globin synthesis. *Br J Hematol*. 1995; 90: 557–63.
3. Schwartz EC, Benz EJ. The Thalassemia syndromes. In: Hoffman R, editor. *Hematology: basic principles and practice*. 1st ed. New York: Churchill Livingstone; 1991.p.368–91.
4. Fucharoen S, Siritanarakul N, Winichagoon P, Chowthawom J, Siriboon W, Muangsup W, et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β -thalassemia/ Hemoglobin E disease. *Blood*. 1996; 87: 887–92.
5. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *New Engl J Med*. 1995; 332: 1317–22.
6. Stamatoyannopoulos JA, Neinhuis AW. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. *Ann Rev Med*. 1992; 43: 497–521.
7. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. *New Engl J Med*. 1990; 332: 1037–45.
8. Valder R, Carmem SP, Fernando F. Successful use of hydroxyurea in beta-thalassemia major. *New Engl J Med*. 1997; 336: 964–5.
9. Loukopoulos D, Voskaridou E, Stomoulatou A, Papassotiriou Y, Kalotychou V, Loutradi A, et al. Hydroxurea therapy in thalassemia. *Ann N Y Acad Sci*. 1998; 850: 120–8.
10. Zargari O, Asadi AK, Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia. *Pediatr Dermatol*. 2004; 21: 633–5.
11. Winichagoon P, Thonglairoam V, Fuchareon S, Wilairat P, Fukumaki Y, Wasi P. Severity differences in beta-thalassemia/HbE syndromes: Implications of genetic factors. *Br J Hematol*. 1993; 83: 633–53.